Bone RemodelingNCT07387458
Bone Turnover Markers and Vitamin D Survey Among Health Professionals in Taiwan
An observational study of Bone Remodeling and Vitamin D, run by National Cheng-Kung University Hospital at 1 site in Taiwan.
Trial summary
This study will provide the first national overview of BTM and vitamin D utilization among healthcare professionals in Taiwan. The findings are expected to inform educational strategies, optimize clinical implementation, and support evidence-based policy development for osteoporosis management. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Bone Remodeling, Vitamin D
- How many people
- 432 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Dec 2024to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Healthcare professionals participating in osteoporosis-related courses
Who may be able to join
- Healthcare professionals participating in osteoporosis-related courses
Who cannot join
- Diseases that may affect bone metabolism, such as cancer, stroke, or mobility impairment
- Use of medications that significantly affect bone metabolism, such as selective estrogen receptor modulators, bisphosphonates, denosumab, anabolic agents, or estrogen
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Perception, Attitude, and Clinical Practice of Bone Turnover Markers and Vitamin D Among Health Professionals in Taiwan
This study will provide the first national overview of BTM and vitamin D utilization among healthcare professionals in Taiwan. The findings are expected to inform educational strategies, optimize clinical implementation, and support evidence-based policy development for osteoporosis management.
Read the detailed description
Due to socioeconomic progress and improved healthcare, the human lifespan has increased, leading to rapid population aging and making age-related problems such as osteoporosis increasingly prominent. According to Taiwan's 2005-2008 National Nutrition Survey, the prevalence of osteoporosis among people aged 50 and older was 38.3% among women and 23.9% among men. Older adults with osteoporosis who suffer hip fractures often experience a high mortality rate. Data from Taiwan's National Health Insurance Administration shows that the one-year mortality rate for older men with hip fractures is 22%, and for women it is 15%, significantly higher than the average mortality rate for the same age group. Those who survive often require long-term care due to their inability to live independently and frequently experience refractures, further increasing the caregiving burden. Early diagnosis and appropriate intervention can prevent fractures, increasing survival time and quality of life.
Bone turnover markers (BTMs) are metabolites produced during bone formation and bone resorption. Previous studies have shown that BTMs can help predict fracture risk, assess patient adherence to medical advice, and monitor the effectiveness of drug treatment. BTMs can be divided into bone formation markers (BTMs) and bone resorption markers (BRMs). The International Osteoporosis Foundation (IOF), the International Society for Clinical Densitometry (ISCD), and the Taiwanese Osteoporosis Association (TOA) recommend that osteocalcin, bone-specific alkaline phosphatase, and procollagen type 1 amino-terminal propeptide (P1NP) be used clinically for bone formation markers. C-terminal telopeptide of type 1 collagen (CTX) and N-terminal telopeptide of type 1 collagen (NTX) can be used for bone resorption markers. Therefore, in 2021, the TOA, together with other international experts, published "Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific region". This statement aims to provide a reference for short-term monitoring of osteoporosis treatment efficacy and patient medication adherence, as well as for predicting future fracture risk.
Previous studies have shown that only 10% of physicians practicing in hospitals and 8% practicing in primary care use bone turnover markers (BTMs) for the diagnosis and treatment of osteoporosis; only 6.2% of patients hospitalized for fractures are advised to use BTMs for the diagnosis and treatment of osteoporosis. There is limited literature on the current clinical application of BTMs.
Therefore, this study surveyed all medical professionals attending osteoporosis-related conferences using a structured questionnaire to examine their awareness, attitudes, and current clinical use of bone turnover markers in Taiwan.
- Conditions
- Bone Remodeling, Vitamin D
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthcare professionals | Healthcare professionals participating in osteoporosis-related courses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bone formation marker
Bone formation marker concentration
Measured: The enrollment day
Vitamin D
Vitamin D concentration
Measured: The enrollment day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Dec 2024
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bone RemodelingStudies of the same condition, open and under way.
- More trials run by National Cheng-Kung University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 432 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cheng-Kung University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chih-Hsing Wu, National Cheng-Kung University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07387458
- Sponsor's protocol ID
- BTM & vit D survey
- Status last verified
- Nov 2025
- First submitted
- 20 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perception, Attitude, and Clinical Practice of Bone Turnover Markers and Vitamin D Among Health Professionals in Taiwan
- ClinicalTrials.gov ID
- NCT07387458
- Acronym / sponsor ID
- BTM & vit D survey
- Conditions
- Bone Remodeling, Vitamin D
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 432 participants (actual)
- Lead sponsor
- National Cheng-Kung University HospitalUniversity, hospital or other
- Study start
- 1 Dec 2024 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will provide the first national overview of BTM and vitamin D utilization among healthcare professionals in Taiwan. The findings are expected to inform educational strategies, optimize clinical implementation, and support evidence-based policy development for osteoporosis management.
Detailed description
Due to socioeconomic progress and improved healthcare, the human lifespan has increased, leading to rapid population aging and making age-related problems such as osteoporosis increasingly prominent. According to Taiwan's 2005-2008 National Nutrition Survey, the prevalence of osteoporosis among people aged 50 and older was 38.3% among women and 23.9% among men. Older adults with osteoporosis who suffer hip fractures often experience a high mortality rate. Data from Taiwan's National Health Insurance Administration shows that the one-year mortality rate for older men with hip fractures is 22%, and for women it is 15%, significantly higher than the average mortality rate for the same age group. Those who survive often require long-term care due to their inability to live independently and frequently experience refractures, further increasing the caregiving burden. Early diagnosis and appropriate intervention can prevent fractures, increasing survival time and quality of life.
Bone turnover markers (BTMs) are metabolites produced during bone formation and bone resorption. Previous studies have shown that BTMs can help predict fracture risk, assess patient adherence to medical advice, and monitor the effectiveness of drug treatment. BTMs can be divided into bone formation markers (BTMs) and bone resorption markers (BRMs). The International Osteoporosis Foundation (IOF), the International Society for Clinical Densitometry (ISCD), and the Taiwanese Osteoporosis Association (TOA) recommend that osteocalcin, bone-specific alkaline phosphatase, and procollagen type 1 amino-terminal propeptide (P1NP) be used clinically for bone formation markers. C-terminal telopeptide of type 1 collagen (CTX) and N-terminal telopeptide of type 1 collagen (NTX) can be used for bone resorption markers. Therefore, in 2021, the TOA, together with other international experts, published "Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific region". This statement aims to provide a reference for short-term monitoring of osteoporosis treatment efficacy and patient medication adherence, as well as for predicting future fracture risk.
Previous studies have shown that only 10% of physicians practicing in hospitals and 8% practicing in primary care use bone turnover markers (BTMs) for the diagnosis and treatment of osteoporosis; only 6.2% of patients hospitalized for fractures are advised to use BTMs for the diagnosis and treatment of osteoporosis. There is limited literature on the current clinical application of BTMs.
Therefore, this study surveyed all medical professionals attending osteoporosis-related conferences using a structured questionnaire to examine their awareness, attitudes, and current clinical use of bone turnover markers in Taiwan.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthcare professionals | – | –Healthcare professionals participating in osteoporosis-related courses |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Healthcare professionals participating in osteoporosis-related courses
Key inclusion criteria (1 listed)
- Healthcare professionals participating in osteoporosis-related courses
Key exclusion criteria (2 listed)
- Diseases that may affect bone metabolism, such as cancer, stroke, or mobility impairment
- Use of medications that significantly affect bone metabolism, such as selective estrogen receptor modulators, bisphosphonates, denosumab, anabolic agents, or estrogen
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Bone formation marker
Time frame: The enrollment day
Bone formation marker concentration
Vitamin D
Time frame: The enrollment day
Vitamin D concentration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Bone Remodeling
Active, not recruiting
Optimal Meals to Reduce Bone Resorption in Women With Osteopenia
Osteopenia
Active, not recruitingPhase 2
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial
Type 2 Diabetes, Osteopenia
Not yet recruiting
Frontal Reconstruction Without Orbital Advancement for Moderate Metopic Craniosynostosis
Metopic Craniosynostosis, Craniosynostosis
Active, not recruiting
Polarstem Versus Corail; a Comparison of Micromotion and Periprosthetic Bone Remodelling of Two Femoral Stems
Arthritis of the Hip
RecruitingObservational study
The CPH-MBD Cohort
Chronic Kidney Disease Mineral and Bone Disorder, Chronic Kidney Disease (CKD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bone Remodeling and Vitamin D, run by National Cheng-Kung University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bone formation marker (time frame: The enrollment day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.